Cargando…
Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
The COVID-19 pathomechanism depends on (i) the pathogenicity of the virus, (ii) ability of the immune system to respond to the cytopathic effect of the virus infection, (iii) co-morbidities. Inflammatory cytokine production constitutes a hallmark of COVID-19 that is facilitated by inability of adapt...
Autores principales: | Lange, Andrzej, Lange, Janusz, Jaskuła, Emilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206782/ https://www.ncbi.nlm.nih.gov/pubmed/34149697 http://dx.doi.org/10.3389/fimmu.2021.658896 |
Ejemplares similares
-
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018) -
Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018) -
Anti-CMV-IgG Positivity of Donors Is Beneficial for alloHSCT Recipients with Respect to the Better Short-Term Immunological Recovery and High Level of CD4+CD25high Lymphocytes
por: Jaskula, Emilia, et al.
Publicado: (2015) -
CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
por: Jaskula, Emilia, et al.
Publicado: (2012) -
Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)